medigraphic.com
ISSN 1561-3054 (Electronic)

2022, Number 2

<< Back

Rev Cubana Med Trop 2022; 74 (2)

Recurrent American visceral leishmaniasis in a kidney transplant recipient: A case report

Alexandre RE, Perinetti AMC, de Melo AI, Pavanetti LC, Aparecida RC, Buzinaro SR, Perinetti AML

Language: English
References: 18
Page:
PDF size: 177.28 Kb.


ABSTRACT

Introduction: American visceral leishmaniasis (AVL) is a neglected tropical disease that causes severe conditions in immunosuppressed patients such as kidney transplant recipients. In these individuals, the infection can be associated with renal graft dysfunction and loss.
Objective: To describe the case of a female kidney transplant recipient assisted at the Hospital das Clínicas of Marília Medical School, who died probably as a result of hemodialysis-related complications after graft loss due to treatment toxicity of her underlying disease.
Clinical case: A 22-year-old patient, resident in an endemic region of AVL, immunosuppressed due to renal transplantation, who evolved to graft loss after successive relapses, treatment and drug prophylaxis for AVL. With the interruption of immunosuppressive therapy and return to dialysis, amastigote forms were not observed in a bone marrow aspirate smears. However, after one year, she progressed to death due to a cerebrovascular accident resulting from comorbidities.
Conclusions: It is described a rare case of successive relapses of AVL and difficult medical decision due to the therapeutic impasse between the use of immunosuppressive drugs for renal graft maintenance and treatment for the parasitic disease. The parasitological control was observed with the immunosuppression suspension, demonstrating the importance of a competent immune system and the adjuvant of specific drugs for the disease control.


REFERENCES

  1. Stolk WA, Kulik MC, le Rutte EA, Jacobson J, Richardus JH, Vlas SJ, et al. Between-Country Inequalities in the Neglected Tropical Disease Burden in 1990 and 2010, with Projections for 2020. PLoS Negl Trop Dis. 2016;10(5):e0004560.

  2. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R. Leishmaniasis: a review. F1000 Research. 2017;6:750.

  3. Organização Pan-Americada da Saúde. Leishmanioses: Informe epidemiológico nas Américas. Núm.9, dezembro de 2020. Washington, D.C.: OPAS; 2020.

  4. Rancan EA, Chagas EFB, Sperança MA, Carvalho VCL, Martins LPA, Suzuki RB. Spatio-temporal distribution of human American visceral leishmaniasis in the Western region of Sao Paulo State, from 2004 to 2018. Ver Inst Med Trop São Paulo. 2020;62.

  5. Viana LG, Assis TS, Orsini M, Silva AR, Souza GF, Caligiorne R, et al. Combined diagnostic methods identify are markable proportion of asymptomatic Leishmania (Leishmania) chagasi carriers who present modulated cytokine profiles. Trans R Soc Trop Med Hyg. 2008 Jun;102(6):548-55.

  6. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol. 2003;97(Suppl 1):3-15.

  7. Coster LO. Parasitic infections in solid organ transplant recipients. Infect Dis Clin North Am. 2013;27(2):395-427.

  8. Ministério da Saúde Brasil. Secretaria de Vigilância em Saúde. Guia de Vigilância em Saúde. Volumen único [recurso eletrônico] / Ministério da Saúde, Secretaria de Vigilância em Saúde, Coordenação-Geral de Desenvolvimento da Epidemiologia em Serviços. 3ª. ed. Brasília: Ministério da Saúde; 2019 [Access 10/24/2021]. 740 p. Available from: https://bvsms.saude.gov.br/bvs/publicacoes/guia_vigilancia_saude_3ed.pdf8.

  9. Sánchez FC, Sánchez TV, Díaz MC, Moyano VES, Gallego CJ, Marrero DH. Visceral Leishmaniasis in Renal Transplant Recipients: Report of 2 Cases. Transplantation Proceedings. 2018;50(2):581-2.

  10. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbellino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8(3):191-9.

  11. Romero GAS, Costa DL, Costa CHN, Almeida RP, Melo EV, Carvalho SFG, et al. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial. PLoS Negl Trop Dis. 2017;11(6):e0005706.

  12. Silva AA, Pacheco-Silva A, Castro CSR, Esmeraldo RM, Oliveira CMC, Fernandes PF, et al. The risk factors for and effects of visceral leishmaniasis in graft and renal transplant recipients. Transplantation. 2013;95(5):721-7.

  13. Boletis JN, Pefanis A, Stathakis C, Helioti H, Kostakis A, Giamarellou H. Visceral leishmaniasis in renal transplant recipients: successful treatment with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1999 Jun;28(6):1308-9.

  14. Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis. 2009 Jan 15;48(2):e16-22.

  15. Rigo RS, Rigo L, Honer MR. Alteração na função renal e pancreatite: efeitos adversos do tratamento da leishmaniose visceral. Arq Ciênc Saúde. 2008:139-41.

  16. Medrano FJ, Jiménez-Mejías E, Calderón E, Regordan C, Leal M. Na easy and quick method for the diagnosis of visceral leishmaniasis in HIV-1-infected individuals. AIDS (London, England). 1993;7(10):1399.

  17. Parasitic infections. Am J Transplant. 2004;4(s10):142-55.

  18. Ghoshal S, Freedman BI. Mechanisms of Stroke in Patients with Chronic Kidney Disease. Am J Nephrol. 2019;50(4):229-39.




2020     |     www.medigraphic.com